These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30868968)

  • 1. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
    CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
    Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
    Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
    Kambey PA; Liu WY; Wu J; Tang C; Buberwa W; Saro A; Nyalali AMK; Gao D
    CNS Neurosci Ther; 2023 Oct; 29(10):2925-2939. PubMed ID: 37101388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
    Dias CMV; Leal DAB; Brys I
    Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
    [No Abstract]   [Full Text] [Related]  

  • 7. Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
    Lago-Rodriguez A; Ponzo V; Jenkinson N; Benitez-Rivero S; Del-Olmo MF; Hu M; Koch G; Cheeran B
    Exp Brain Res; 2016 Dec; 234(12):3659-3667. PubMed ID: 27566172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    LeWitt PA; Stebbins GT; Christensen KV; Tan R; Pretorius A; Thomsen M
    Mov Disord; 2024 Mar; 39(3):613-618. PubMed ID: 38314643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced Dyskinesia in Parkinson's Disease: Plausible Inflammatory and Oxidative Stress Biomarkers.
    Sarkar S; Roy A; Choudhury S; Banerjee R; Dey S; Kumar H
    Can J Neurol Sci; 2024 Jan; 51(1):104-109. PubMed ID: 36660782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease.
    Soares NM; Pereira GM; Dutra ACL; Artigas NR; Krimberg JS; Monticelli BE; Schumacher-Schuh AF; Almeida RMM; Rieder CRM
    Arq Neuropsiquiatr; 2023 Jan; 81(1):40-46. PubMed ID: 36918006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A video-atlas of levodopa-induced dyskinesia in Parkinson's disease: terminology matters.
    Gupta HV; Lenka A; Dhamija RK; Fasano A
    Neurol Sci; 2024 Apr; 45(4):1389-1397. PubMed ID: 37987930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microstructural and functional alterations of the ventral pallidum are associated with levodopa-induced dyskinesia in Parkinson's disease.
    Gan Y; Su D; Zhang Z; Zhang Z; Yan R; Liu Z; Wang Z; Zhou J; Lam JST; Wu T; Jing J; Feng T
    Eur J Neurol; 2024 Feb; 31(2):e16147. PubMed ID: 37975786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia.
    Fujita K; Peng S; Ma Y; Tang CC; Hellman M; Feigin A; Eidelberg D; Dhawan V
    J Neurol; 2021 Jun; 268(6):2246-2255. PubMed ID: 33502551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
    Liu JS; Chen Y; Shi DD; Zhang BR; Pu JL
    Curr Neuropharmacol; 2023; 21(3):536-546. PubMed ID: 36582064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia.
    Riggare S; Unruh KT; Sturr J; Domingos J; Stamford JA; Svenningsson P; Hägglund M
    Methods Inf Med; 2017 Oct; 56(99):e123-e128. PubMed ID: 29064509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relationship of levodopa with dyskinesia in Parkinson's disease: A systematic review and meta-analysis.
    He T; Wang D; Zhang X; Liu J; Fang S; Zhang Z; Liu H
    Heliyon; 2024 Mar; 10(6):e27956. PubMed ID: 38515703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
    Isaacson SH; Fahn S; Pahwa R; Tanner CM; Espay AJ; Trenkwalder C; Adler CH; Patni R; Johnson R
    Mov Disord Clin Pract; 2018; 5(2):183-190. PubMed ID: 29780852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
    Martinez-Carrasco A; Real R; Lawton M; Iwaki H; Tan MMX; Wu L; Williams NM; Carroll C; Hu MTM; Grosset DG; Hardy J; Ryten M; Foltynie T; Ben-Shlomo Y; Shoai M; Morris HR
    medRxiv; 2023 May; ():. PubMed ID: 37425912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice.
    Caronni S; Del Sorbo F; Barichella M; Fothergill-Misbah N; Denne T; Laguna J; Urasa S; Dekker MCJ; Akpalu A; Sarfo FS; Cham M; Pezzoli G; Cilia R
    Parkinsonism Relat Disord; 2024 Jul; 124():106983. PubMed ID: 38797572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Han C; Zhao ZZ; Chan P; Li F; Chi CL; Zhang X; Zhao Y; Chen J; Ma JH
    Vaccine; 2023 Oct; 41(43):6483-6494. PubMed ID: 37726180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.